Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Working Capital Changes (2018 - 2025)

10x Genomics' Other Working Capital Changes history spans 8 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 2748.46% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $2.3 million, up 201.93%, while the annual FY2025 figure was $2.3 million, 201.93% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $3.7 million at 10x Genomics, up from $3.6 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $7.5 million in Q4 2022 and bottomed at -$4.8 million in Q2 2023.
  • The 5-year median for Other Working Capital Changes is -$242500.0 (2021), against an average of $362350.0.
  • The largest annual shift saw Other Working Capital Changes tumbled 1234.48% in 2024 before it surged 2748.46% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$697000.0 in 2021, then skyrocketed by 1175.75% to $7.5 million in 2022, then crashed by 99.61% to $29000.0 in 2023, then skyrocketed by 348.28% to $130000.0 in 2024, then soared by 2748.46% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Other Working Capital Changes are $3.7 million (Q4 2025), $3.6 million (Q3 2025), and -$2.4 million (Q2 2025).